> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# KemPharm NDA for ADHD Prodrug
- URL: https://www.fdaweb.com/kempharm-nda-for-adhd-prodrug/
- Published: 2020-03-03T12:00:00.000Z
- Updated: 2026-09-14T16:05:26.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5146230

KemPharm has submitted a 505(b)(2) for serdexmethylphenidate, indicated for treating attention deficit hyperactivity disorder. Serdexmethylphenidate is KemPharm’s prodrug of d-methylphenidate, the company says, adding that it has a 30 minute onset of action, a duration effect of 13 hours, and avoids unnecessary spikes in d-methylphenidate that may be associated with adverse events. If deemed reviewable by the agency, the company expects a 3/2021 user fee review action target date.